AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05533476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Usual Care (Upper Limb)
Description: The Intensive Usual Care (Upper Limb) intervention is a more intensive (in duration and frequency) version of standard Usual Care with focus on the motor development of the affected upper extremity. Upper extremity motor activities like reaching, grasping and holding are practiced. Parents practice daily and once a week the training will be guided or conducted by a physical or occupational therapist in the home environment. An occupational therapist from the rehabilitation center will coach parents during the intervention period through the internet, by means of analyzing the videos from the home training.
Study NCT05270421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Description: Standard ESWL + Furosemide 40 mg
Study NCT03850574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Venetoclax will be given to study participants in the Part C tuspetinib plus venetoclax combination treatment group either in 50 mg or 100 mg tablets
Study NCT03850574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine for Intravenous Infusion
Description: Azacitidine will be given to study participants in Part D as intravenous infusion at a dose of 75 mg/m\^2
Study NCT05270421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Standard ESWL
Study NCT05270421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Standard ESWL
Study NCT01180530 — intervention group
Intervention type: DEVICE
Intervention: NovoPen Echo®
Description: Prescribed insulin treatment delivered by NovoPen Echo®
Study NCT04231318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Single intra-articular injection of Cingal into the knee.
Study NCT04231318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide (TH)
Description: Single intra-articular injection of TH into the knee.
Study NCT04231318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection Placebo (0.9% Saline) into the knee.
Study NCT00381381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
Study NCT04246736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bädda för Kvalitet
Description: A group-administered preventive programme focusing on beneficial strategies for sleep and recuperation, in relation to work related stress and shift work. The intervention was based on knowledge from previous research on sleep, stress and work hours, as well as on cognitive behavioural therapy (CBT) techniques for sleep and stress management, modified for shift workers. Participants were encouraged to discuss and reflect on personal habits related to sleep and recovery. As homework between sessions, the participants were encouraged to try possibly beneficial strategies for sleep and recuperation. All participants got written material covering the content of the session, during each sessions. In addition, an adapted version of a biomathematical model (ArturNurse) was used to give participants an estimation of expected sleep lengths and fatigue levels together with tips of possible strategies to optimise sleep in relation to different shifts.
Study NCT02943252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500 mg in tablet once daily
Study NCT02943252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 40-60mg bid, days 1-14 , every 3 weeks
Study NCT03784287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX 250
Description: Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
Study NCT04315935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and Propofol
Description: The two groups were given propofol for sedation, BG for butorphanol for analgesia and FG for fentanyl for analgesia
Study NCT04315935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and Propofol
Description: Fentanyl (0.7-10 μ g / kg / h) analgesia and Propofol (1-4 mg / kg / h) sedation
Study NCT00989573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration of placebo once-daily for 8 weeks
Study NCT00989573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-6535
Description: oral administration of OPC-6535 25 mg once-daily for 8 weeks
Study NCT00989573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-6535
Description: oral administration of OPC-6535 50 mg once-daily for 8 weeks
Study NCT04059198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inarigivir soproxil
Description: Inarigivir soproxil 400 mg tablets
Study NCT04059198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide fumarate (TAF)
Description: Tenofovir alafenamide fumarate 25 mg tablet
Study NCT04654884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture (AA)
Description: The add-on treatment will be administered at the treatment sessions with their caregiver (i.e. registered nurse, psychologist, curator), and at each session the participants receive 5 sterile stainless needles in each outer ear. The needling is standardised according to the NADA-protocol. The needles will remain in the outer ears for approximately 45 minutes, and will be removed by the care giver.
Study NCT02273518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation I
Study NCT02273518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER, new formulation II
Study NCT02273518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER, present commercial formulation
Study NCT03193125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: 500 mg tablets of L-Carnitine taken 3 times daily before meals.
Study NCT03193125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg tablets of L-Carnitine taken 3 times daily before meals.
Study NCT03750422 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picoway
Description: 1064/532nm picosecond laser
Study NCT03750422 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Picoway
Description: 1064/532nm picosecond laser
Study NCT03750422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stratacel
Description: a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
Study NCT03594656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ganoderma
Description: 0.8g twice daily
Study NCT03594656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma
Description: 0.8g twice daily
Study NCT04142658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: On-X Aortic Mechanical Valve
Description: Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
Study NCT04142658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-X Aortic Mechanical Valve
Description: Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
Study NCT03594656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.8g twice daily
Study NCT03303066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral
Study NCT03303066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT04298333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injection, will be administered intramuscularly once per day. The cumulative dose range will be 0.64-1.12 mg/kg body weight depending on design level (design level 1-3). The daily dose range will be 0.02-0.035 mg/kg body weight (0.04-0.07 mL/kg) depending on design level (design level 1-3).~Dose level 1: 0.02 mg/kg body weight (0.04 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 2: 0.03 mg/kg body weight (0.06 mL/kg) intramuscularly once daily for 32 consecutive days; dose level 3: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days.~Changes in the cumulative dose of BP-C1 between patients in the sequence are predefined and will be adjusted by escalation/deescalation rules based on changes in toxicity observed in the previous design level.~The duration of BP-C1 treatment will be 32 days.
Study NCT03115463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of oxygen during neonatal resuscitation
Description: Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
Study NCT03115463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen during neonatal resuscitation
Description: Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
Study NCT02356653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)
Description: Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
Study NCT03098706 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Procedure control: normothermia
Description: Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
Study NCT03098706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure active
Description: Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
Study NCT03139266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT
Description: Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
Study NCT03139266 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: The control group will receive the recommendation to consider maintaining mental health services
Study NCT03750422 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aquasonic
Description: clear ultrasound gel
Study NCT02240290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozadenant tablet
Description: Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
Study NCT03933631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
Study NCT03933631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone acetate ophthalmic suspension 1%
Study NCT03933631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone acetate ophthalmic suspension 1%
Study NCT03933631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Ofloxacin Drops
Study NCT03933631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin
Description: Ofloxacin Drops
Study NCT01555424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose
Description: This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
Study NCT01555424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference dose
Description: This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
Study NCT00706537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: 20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
Study NCT00706537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as two tablets once daily for three weeks
Study NCT02440165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing nutrition intervention
Description: The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~* Information and advice;~* Examples of energy and protein rich meals;~* patients will be asked to register their nutritional intake for two days at home;~* after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care.
Study NCT00832026 — intervention group
Intervention type: DEVICE
Intervention: Trans Nasal Insufflation (TNI) [nasal canula]
Description: Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing.
Study NCT05007860 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Description: Vaccines administered per standard of care
Study NCT03422887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine administration during surgery
Study NCT03422887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen axetil administration during surgery
Study NCT03422887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine and Flurbiprofen Axetil
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Study NCT04903769 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management and Resiliency Training Program for Parkinson's Disease (SMART-PD)
Description: SMART-PD is a manualized intervention that teaches cognitive-behavioral techniques and relaxation skills to help participants learn to elicit the relaxation response, alter cognitive appraisals, improve healthy lifestyle behaviors (i.e., sleep, nutrition, physical activity) and access social support.
Study NCT03133377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early activity and mobilisation
Description: The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
Study NCT01714063 — intervention group
Intervention type: DEVICE
Intervention: Pressurized Metered-Dose Inhaler
Description: Pressurized Metered-Dose Inhaler
Study NCT02136355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy plus Surgery
Description: Stereotactic body radiation therapy followed by surgical resection
Study NCT02338557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: motor relearning programme
Description: MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
Study NCT02338557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIRROR THERAPY
Description: Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
Study NCT03063164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intralase IFS150
Description: Intralase flap creation
Study NCT03063164 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visumax
Description: Visumax flap creation
Study NCT05912725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: 4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar~4 implants were placed , 2 implants in each side of the patient mouth opposite lower second premolar and second molar
Study NCT02240290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C14-tozadenant capsule
Description: Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
Study NCT03300687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: intratympanic injection
Study NCT03300687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intratympanic injection
Study NCT01341405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG100649
Description: once daily for 28 days
Study NCT01341405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: capsule, celecoxib 200 mg, once daily for 28 days
Study NCT04346680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ADSC administration
Description: The treated nerve will be identified and released. Scar tissue will be removed, and nerve fibers will be exposed. Prepared solutions of ADSC will be administered via microinjection with a 30-G needle along the released nerve fascicles, above and below the reconstructed area and around the adjacent tissue, which stayed in contact with the nerves.
Study NCT02010034 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omegaven
Description: Omegaven will be used in place of soy oil Intralipid
Study NCT01199653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative treatment
Description: Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
Study NCT01199653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment with arm immobilised to a sling
Description: Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
Study NCT04238962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (administered by DV3396 pen-injector)
Description: Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 7 weeks
Study NCT04238962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide (administered by PDS290 pen-injector)
Description: Increasing doses of semaglutide given sc in the stomach for 7 weeks
Study NCT01021501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine controlled release tablets
Description: nifedipine controlled release tablets 60mg/day for at least 4 weeks
Study NCT02284139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm EGF ointment 1ppm
Description: EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
Study NCT02284139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm EGF ointment 20 ppm
Description: EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day